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Factors inﬂuencing the initiation or progression of sclerosis in patients with systemic sclerosis (SSc) are poorly
understood. Monocyte chemotactic protein-1 (MCP-1) is a potent chemokine, which is upregulated in ﬁbroblasts
during development of sclerosis. In this study, we investigated the frequency of the functional 2518G MCP-1
promoter polymorphism in 18 patients with SSc and 139 healthy controls. In the lesional skin of the same SSc
patients, expression of MCP-1 protein was examined by immunohistochemistry. To investigate a genotype/phe-
notype correlation, basal as well as tumor necrosis factor (TNF)-induced MCP-1 expression was analyzed in ﬁb-
roblasts isolated from the skin of SSc patients with different MCP-1 genotypes by quantitative RT-PCR and ELISA.
Genotyping for the 2518 (A/G) MCP-1 promotor polymorphism showed that GG homozygotes were significantly
more frequent in patients with SSc than in controls (28% vs 6%). Results of immunohistochemistry revealed
that MCP-1 was expressed in keratinocytes, inﬁltrating inﬂammatory cells, ﬁbroblasts, and endothelial cells in
scleroderma skin, whereas normal control skin showed no MCP-1 expression. MCP-1 expression in ﬁbroblasts
from GG-homozygote individuals tended to be stronger as compared to AG or AA genotypes. Furthermore, basal as
well as TNF-induced MCP-1 expression of ﬁbroblasts isolated from a GG-homozygote SSc patient was significantly
higher than MCP-1 expression of ﬁbroblasts isolated from heterozygote or AA-homozygote donors. The A 2518G
polymorphism of the MCP-1 gene appears to affect MCP-1 expression of skin ﬁbroblasts of patients with SSc. In
accordance, the G/G genotype may predispose patients to SSc.
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Systemic sclerosis (SSc) is a rare autoimmune disease of
the connective tissue characterized by sclerosis of the skin,
subcutaneous tissue, and internal organs. One of the char-
acteristic histological features in SSc is the presence of in-
filtrating mononuclear cells in the dermis in early stages in
association with an increase in collagen synthesis. It is
generally accepted that dermal fibroblasts play a crucial
role in the pathogenesis of skin sclerosis by synthesizing
increased amounts of collagen types I, III, VI, and VII,
glycosaminoglycans, decorin, and fibronectin, whereas col-
lagen degrading enzymes (matrix-metalloproteinases:
MMP-1, -2, -3) are decreased (Hawk and English, 2001).
The cause of the increased collagen synthesis is still not
elucidated, however, inflammatory cells are regarded to be
candidates for releasing cytokines that initiate and/or result
in the sequential events of fibrosis and in perpetuation of the
pathophysiologic process (Kovacs and DiPietro, 1994).
Chemokines are a large family of small cytokines with
potent chemoattractive effects on specific leukocyte sub-
sets, which can also induce a variety of cellular responses
such as angiogenesis or matrix protein synthesis. Chemo-
tactic cytokines are known to be critical mediators of cell
trafficking into sites of injury and therewith modulators of
tissue injury, inflammation and repair. Of these, monocyte
chemotactic protein-1 (MCP-1) is one of the most potent
chemokines especially for monocytes and macrophages
(Boring et al, 1999). It belongs to the group of CC
chemokines with two conserved adjacent cysteine resi-
dues. Recent studies have shown that MCP-1 expession is
upregulated in fibrotic processes, including acute hepatic
fibrogenesis (Marra et al, 1998), interstitial kidney fibrosis
(Lloyd et al, 1997) as well as human idiopathic pulmonary
fibrosis (Antoniades et al, 1992). In vitro studies have dem-
onstrated that MCP-1 stimulates type I collagen gene ex-
pression in rat lung fibroblasts and in normal skin fibroblasts
(Gharaee-Kermani et al, 1996; Yamamoto et al, 2001b).
These results provide evidence that enhanced MCP-1 ex-
pression contributes to the development of tissue fibrosis
by various mechanisms, although little is known about the
factors, which regulate MCP-1 gene expression.
SSc fibroblasts have been shown to display an array of
chemokines including an increased and abnormally regu-
lated expression of MCP-1 in vitro (Galindo et al, 2001;
Yamamoto et al, 2001a, b). In addition to the highly in-
creased expression of MCP-1, in vitro SSc fibroblasts
are more responsive to MCP-1, which could result in an
Abbreviations: MCP-1, monocyte chemotactic protein-1; SSc,
systemic sclerosis; TNF, tumor necrosis factor
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autocrine stimulation, perpetuation, and maintenance of
hyperactivity of the SSc fibroblasts and the fibrotic process
(Yamamoto et al, 2001b). Also in vivo, increased MCP-1
expression was found in fibroblasts derived from lesional
skin of patients with SSc (Galindo et al, 2001; Yamamoto
et al, 2001a, b). In these previous studies, MCP-1 expres-
sion correlated with the infiltration of mononuclear cells
suggesting that MCP-1 plays a role in recruiting monocyte/
macrophages to the lesional skin of SSc and that activated
fibroblasts are involved in this process. Furthermore, ele-
vated serum levels of MCP-1 were found in patients with
SSc, which correlated with the presence of pulmonary fi-
brosis (Hasegawa et al, 1999).
Previous in vitro studies with different human cell types
including peripheral blood mononuclear cells or activated
hepatic stellate cells/myofibroblasts revealed considerable
interindividual variability in basal as well as in cytokine-in-
duced MCP-1 expression (Sylvester et al, 1993; Rovin et al,
1999; Kruger et al, 2002; Muhlbauer et al, 2003), suggesting
that inherited factors influence the expression of this
chemokine. Interestingly, also in vitro MCP-1 production of
systemic fibroblast cell lines revealed considerable variation
(Galindo et al, 2001).
Recently, a polymorphism in the distal regulatory region
of the MCP-1 gene at position 2518 relatively to the tran-
scription start site (based on the published sequence Gene
Bank accession number D26087) was identified (Rovin et al,
1999). The functional relevance of this polymorphism has
been shown by several in vitro studies analyzing cytokine-
induced MCP-1 expression of peripheral blood mononu-
clear cells or activated hepatic stellate cells/myofibroblasts
(Rovin et al, 1999; Kruger et al, 2002; Muhlbauer et al, 2003).
Cells from individuals carrying the G-allele at 2518 ex-
pressed more MCP-1 than cells from A/A homozygous
subjects. Moreover, the prevalence of these high MCP-1-
producing genotypes has been shown to be associated
with the presence and severity of bronchial asthma (Szalai
et al, 2001), the risk for premature kidney graft failure
(Kruger et al, 2002), the onset and disease behavior of
Crohn’s disease (Herfarth et al, 2003), the frequency of cut-
aneus vasculitis (Aguilar et al, 2001) and fibrosis progression
in patients with chronic hepatitis C infection (Muhlbauer
et al, 2003). Furthermore, it has been postulated to be a
genetic risk factor for severe coronary artery disease (Szalai
et al, 2001). The role of this genetic polymorphism, however,
in SSc has not yet been investigated.
In this study, we investigated the hypothesis that the
presence of the high MCP-1 producing G-allele may pre-
dispose to or support the development of SSc. The aims of
this study were (1) to examine the prevalence of this po-
lymorphism in patients with SSc as compared to normal
controls, (2) to evaluate whether the expression of MCP-1 in
the patients tissue correlates with the patients genotype,
and (3) to investigate a genotype/phenotype correlation by
analyzing MCP-1 expression in fibroblasts from donors with
different MCP-1 genotypes.
Results
Frequency of the 2518 MCP-1 polymorphism in patients
with SSc and healthy controls The frequencies of the
individual genotypes of the control group were similar to
those previously reported in other Caucasian control popu-
lations (Aguilar et al, 2001; Szalai et al, 2001a, b; Kruger et al,
2002), and in patients, as well as controls, individual geno-
types were found to be in the Hardy–Weinberg equilibrium.
G/G-homozygote SSc-patients, A/G heterozygotes and
non-G-allele carriers (A/A-homozygotes) did not differ sig-
nificantly with regard to the distribution of demographic
features, e.g., age (G/G: 48.8  18.4 y, A/G: 58.6  6.8 y,
A/A: 56.7  13.5 y) or gender (G/G: 1m/4w, A/G: 1m/4w,
A/A: 2m/6w).
Carriers of the G-allele were more frequent in patients
with SSc as compared to controls (ten of 18 (56%) vs 68 of
139 (48%), respectively) although these differences did not
reach statistical significance.
Despite the relatively small sample size, however, the
frequency of G/G-homozygotes was significantly higher in
SSc patients than in controls (five of 18 (28%) vs nine of 139
(6%), respectively; p¼0.023 based on Fischer’s Exact Test)
(Table I).
Characterization of MCP-1 expression by immunohisto-
chemistry Next, we investigated MCP-1 expression in les-
ional skin of SSc patients with different MCP-1 genotypes
by immunohistochemistry. Specimens from healthy sub-
jects and from patients with inflammatory skin disorders
(contact dermatitis, vasculitis, urticaria, eczema) served as
controls. Although no immunosignal was detectable in nor-
mal skin (Fig 1A), immunostaining of scleroderma skin re-
vealed MCP-1 expression in keratinocytes, inflammatory
cells, fibroblasts, and endothelial cells (Fig 1B–D).
As cellular source of MCP-1 expression, we found infil-
trating inflammatory cells in patients with an inflammatory
stage of SSc (Fig 1B) as well as in positive controls (contact
dermatitis, vasculitis, urticaria, eczema) (Fig 1E ). Weak,
moderate or strong MCP-1 expression was detected in fib-
roblasts of SSc specimens. Interestingly, in contrast this
pronounced MCP-1 expression in fibroblasts could not be
observed in skin specimens of positive controls.
A semiquantitative score was applied to characterize
MCP-1 expression in different cell types. Results are sum-
marized in Table II. Comparing MCP-1 expression in fibro-
blasts from SSc patients with different MCP-1 genotypes
revealed a strong expression of MCP-1 in 60% of the
specimens from GG-homozygote individuals, in 40% of
AG-heterozygote patients and in 37.5% of AA-homozygote
individuals. In the only two patients with an inflammatory
Table I. Frequency of the 2518 MCP-1 polymorphism in








A/A 8 (44) 71 (51)
A/G 5 (28) 59 (42)
G/G 5 (28)a 9 (6)a
aIndicates a significant difference (p¼0.023 based on Fischer’s Exact
Test).
MCP-1, monocyte chemotactic protein-1; SSc, systemic scelorosis.
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stage of SSc (both GG-homozygote), MCP-expression was
most pronounced within the inflammatory infiltrates. All of
the AA and AG groups were in the sclerotic stage of disease
and showed mostly negative MCP-1 expression within the
absent or sparse inflammatory infiltrates. Due to the limited
amount of data, it is difficult to make quantitative state-
ments regarding results of histochemistry.
MCP-1 expression in dermal ﬁbroblasts from individuals
with different MCP-1 genotypes To further analyze the
functional relevance of the MCP-1 promoter polymorphism
in SSc, we investigated the in vitro MCP-1 expression of
three SSc fibroblast cell strains isolated from donors with
different MCP-1 genotypes (A/A, A/G and G/G).
The G/G-homozygote fibroblasts revealed a 4-fold higher
basal MCP-1 mRNA expression as compared to A/G he-
terozygote fibroblasts and a 8.3-fold higher MCP-1 mRNA
expression as compared to A/A homozygote fibroblasts. In
all three cell lines, as tumor necrosis factor (TNF) induced a
significant increase of MCP-1 mRNA compared to unstim-
ulated controls. Also after TNF stimulation GG-homozygote
fibroblasts revealed significantly higher MCP-1 expression
Figure1
Immunohistochemistry of monocyte chemotactic protein-1 (MCP-
1). Minimal staining for MCP-1 is shown in normal control skin (A)
(200). MCP-1 immunolocalization shows staining for MCP-1 protein in
keratinocytes and inflammatory infiltrates of lesional scleroderma skin
(B), in fibroblasts of lesional scleroderma skin (C) and in endothelial
cells of lesional scleroderma skin (D). Strong MCP-1 staining is
detectable in the inflammatory cells in contact dermatitis (E) (800).
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than AA-homozygote (3.1-fold) or heterozygote fibroblasts
(3.4-fold), respectively (Fig 2).
Basal expression of MCP-1 protein as measured by
ELISA was significantly higher in fibroblasts from G/G-
homozygote donors (9452  250 pg per mL) as compared
to A/G heterozygote (4739  1028 pg per mL, p¼0.024)
and A/A homozygote fibroblasts (2355  50 pg per mL,
po0.001). In all three cell lines, TNF induced a significant
increase of MCP-1 expression compared with unstimulated
controls. Also after TNF stimulation GG-homozygote fibro-
blasts (18,921  66.5 pg per mL) revealed significantly
higher MCP-1 secretion than AA-homozygote (3980  500
pg per mL, p¼0.001) or heterozygote fibroblasts
(14,106  379, p¼0.01). TNF induced MCP-1 secretion
was also significantly higher in heterozygote fibroblasts as
compared to AA-homozygote fibroblasts (po0.001) (Fig 3).
Table II. Immunohistochemical detection of MCP-1 in the skin
tissues of SSc patients and correlation with MCP-1 genotype






























1 AA Sclerotic þ  þ þ
2 AA Sclerotic þ   
3 AA Sclerotic þ  þ 
4 AA Sclerotic    
5 AA Sclerotic þ  þ 
6 AA Sclerotic þ þ  þ þ þ
7 AA Sclerotic þ  þ þ þ
8 AA Sclerotic þ þ þ þ þ þ þ
9 AG Sclerotic   þ 
10 AG Sclerotic þ  þ 
11 AG Sclerotic þ  þ 
12 AG Sclerotic þ  þ þ 
13 AG Sclerotic þ þ  þ þ 
14 GG Inflammatory þ þ þ þ þ þ
15 GG Inflammatory þ þ þ þ þ
16 GG Sclerotic þ  þ 
17 GG Sclerotic þ  þ 
18 GG Sclerotic þ þ  þ þ 
Control sections: diagnosis
Vasculitis þ þ þ þ þ þ
Contact dermatitis þ þ þ þ  þ
Contact dermatitis þ þ þ þ  þ
Urticaria þ þ þ  þ þ
Eczema    
aþ þ , strong; þ , moderate; þ , weak; , negative (according to
Yamamoto et al, 2001a, b).
MCP-1, monocyte chemotactic protein-1; SSc, systemic scelorosis.
Figure2
Monocyte chemotactic protein-1 (MCP-1) mRNA expression of
dermal fibroblasts from systemic sclerosis (SSc) donors with dif-
ferent MCP-1 genotypes (A/A, A/G, G/G). MCP-1 mRNA expression
was analysed by quantitative PCR in unstimulated cells (basal expres-
sion, light gray bars) and after stimulation with tumor necrosis factor
(TNF) (10 ng per mL) (dark gray bars) for 6 h. Results shown are rep-
resentative of three independent experiments. Indicates a significant
difference (po0.05).
Figure3
Monocyte chemotactic protein-1 (MCP-1) secretion of dermal fib-
roblasts isolated from systemic sclerosis (SSc) donors with differ-
ent MCP-1 genotypes (A/A, A/G, and G/G). MCP-1 protein secretion
was analysed by ELISA in the supernatants of unstimulated fibroblasts
(basal expression, light gray bars) and after stimulation with tumor
necrosis factor (TNF) (10 ng per mL) (dark gray bars) for 16 h. Results
represent mean  SD. Results shown are representative of three
independent experiments. Indicates a significant difference
(po0.05).
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Discussion
In this study, we could support our hypothesis that inher-
itance of the G-allele of the functional promotor MCP-1 po-
lymorphism A 2518G may contribute to the development
of SSc. We found homozygote carriers of the G-polymorph-
ism to be significantly more frequent in SSc patients than in
healthy controls.
Recently, several important prerequisites for the design
of association trials were recommended (Ioannidis et al,
2001; Day, 2003). It is important to define (I) a sound ra-
tionale for the candidate genes; (II) a plausible a priori hy-
pothesis based on the functional significance of the studied
polymorphisms; and (III) a detailed characterization of cases
ensuring comparable exposure to the pathogenic trigger.
Furthermore, the study sample (IV) should have a homoge-
neous genetic background to avoid ethnic heterogeneity
and (V) exclude confounding factors. All these requirements
were accounted for in this study. As in most genetic asso-
ciation studies analyzing rare diseases, however, it has to
be taken into account that the number of patients and the
corresponding power of calculation are limited and results
have to be confirmed in other cohorts of patients.
Here, unlike almost all previous genetic association stud-
ies performed in SSc patients so far, we provide additional
functional data indicating the relevance of the MCP-1 po-
lymorphism in SSc.
Chemokines, such as MCP-1, play a pathogenetic role in
SSc, potentially by augmenting leucocyte migration into the
affected tissues (Yamamoto et al, 2001a). Patients with SSc
seem to be predisposed to high MCP-1 production. MCP-1
serum levels as well as spontaneous MCP-1 expression
levels of peripheral blood mononuclear cells have been
shown to be significantly elevated in patients with SSc
compared to normal controls (Hasegawa et al, 1999). Fur-
thermore, elevated serum levels of MCP-1 correlated with
the presence of pulmonary fibrosis in SSc patients (Has-
egawa et al, 1999). Since MCP-1 expression in inflamma-
tory mononuclear cells and endothelial cells was more
frequently detected immunohistochemically in the skin of
SSc patients with short disease duration than in those with
long disease duration, it was suggested that MCP-1 ex-
pression in the skin might contribute to the initiation of skin
sclerosis (Hasegawa et al, 1999). Furthermore, it has been
shown that MCP-1 stimulates collagen synthesis in fibro-
blasts indirectly via endogenous upregulation of transform-
ing growth factor-b expression (Gharaee-Kermani et al,
1996). Also in dermal sclerosis, MCP-1 has been suggested
to contribute to the increased fibrosis via its direct effect on
the upregulation of mRNA expression of extracellular matrix
proteins in fibroblasts, as well as its indirect effect mediated
by a number of cytokines released from proinflammatory
cells recruited into the lesional skin (Yamamoto and
Nishioka, 2003).
The polymorphism at position 2518 of the MCP-1 gene
has been implicated before in the progression of coronary
artery disease, asthma, cutaneous vasculitis, kidney graft
failure, hepatitis C virus-related liver damage and the onset
of Crohn’s disease (Aguilar et al, 2001; Szalai et al, 2001;
Kruger et al, 2002; Herfarth et al, 2003; Muhlbauer et al,
2003). Considering the known pathophysiological role of the
chemokine MCP-1 in these diseases, these examples fur-
ther indicate that the G allele may be the allele associated
with a higher MCP-1 expression in certain inflammatory
conditions. There are few studies, however, investigating
the molecular mechanisms responsible for the effect of the
2518G MCP-1 promoter polymorphism on MCP-1 tran-
scription. Rovin et al (1999) performed in vitro studies using
appropriate reporter plasmids and provided evidence that
the region of the polymorphism is influencing the transcrip-
tional activity of the MCP-1 gene. Moreover, we could re-
cently demonstrate a genotype–phenotype correlation in
activated hepatic stellate cells from donors with different
MCP-1 genotypes (Muhlbauer et al, 2003). Activated he-
patic stellate cells are a myofibroblast-like cell type and are
responsible for the excessive hepatic extracellular matrix
deposition during liver fibrosis. During chronic liver disease
hepatic MCP-1 is mainly secreted by these cells.
Similarly, previous studies identified dermal fibroblasts as
a main source of MCP-1 in scleroderma lesions (Distler et al,
2001; Galindo et al, 2001, Yamamoto et al, 2001a, b). In
accordance, also in this study we could confirm strong
MCP-1 expression in fibroblasts of affected skin biopsies of
SSc patients. Interestingly, this MCP-1 expression in fibro-
blasts was not found in control patients with inflammatory
skin disorders. These findings are in line with a previous
study (Yamamoto et al, 2001a), indicating a specific role of
fibroblasts in the pathogenesis of SSc.
This prompted us to investigate in vitro cultured fibro-
blasts from donors with different 2518 MCP-1 genotypes
to compare their basal and TNF-induced MCP-1 expres-
sion. Proinflammatory cytokines such as TNF and IL-1 are
known to be potent inducers of MCP-1 production (Gu et al,
1999). In line with the above-mentioned findings, we found a
significantly higher expression of MCP-1 mRNA and protein
in fibroblasts from donors carrying at least one G-allele
compared to A/A-homozygotes. Furthermore, cells from the
G/G homozygote donor revealed significantly higher MCP-1
secretion than heterozygotic fibroblasts. Stimulation with
TNF resulted in a significant increase of MCP-1 mRNA and
protein expression. These findings provide further evidence
for the functional relevance of the MCP-1 polymorphism.
Interestingly, in vitro differences between SSc fibroblasts
from donors with different MCP-1 genotypes were evident
also after TNF stimulation. This may indicate the relevance
of this polymorphism in SSc also under inflammatory
conditions.
In SSc, the activation of the immune system is an early
event in the disease process. Fibroblasts play an important
role in the regulation of the immune system, e.g., by the
secretion of chemokines and participate already in the in-
itiation of the disease process (Hogaboam et al, 1998). In-
filtration of the skin with mononuclear cells precedes the
development of fibrosis and vasculopathy (Hawk and Eng-
lish, 2001). Investigation of the mechanisms that initiate and
perpetuate the inflammatory infiltration in SSc is important
for understanding the early steps in the pathogenesis of
the disease. Several lines of evidence indicate that MCP-1
expression in fibroblasts plays an important role in the de-
velopment of fibrosis in SSc. MCP-1 has been shown to
modulate connective tissue deposition by inducing collagen
synthesis (Gharaee-Kermani et al, 1996). Furthermore,
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MCP-1 expression has been shown to induce the proin-
flammatory cytokine IL-1 and to lead to the induction of
signal transduction cascades controlling inflammatory gene
expression as the NFkB system (Hisada et al, 2000; Yama-
moto et al, 2000).
MCP-1 produced by activated fibroblasts in scleroderma
patients could therefore act as a chemoattractant for mono-
nuclear cells, which contribute to the initial inflammatory
infiltrate localized around small blood vessels in the dermis
in early stages of scleroderma and could be involved in the
perpetuation of inflammation. Thus, this chemokine plays
an important role in the complex networks that ultimately
result in tissue fibrosis (Distler et al, 2001).
In summary, the association between 2518 MCP-1 po-
lymorphism and SSc, together with the results that 2581
MCP-1 polymorphism affects mRNA and protein expression
in fibroblasts, suggests that MCP-1 genotyping might pro-
vide a reliable indicator of disease susceptibility and even-
tually also of prognosis of the disease. These findings,
however, have to be confirmed in other cohorts and further
studies have to be performed to fully elucidate the patho-
physiological role of MCP-1 and its functional genetic
polymorphism in SSc.
Materials and Methods
Patients and patients material We investigated 18 patients (14
female, four male; mean age: 55.0  15.0 y), who were admitted
consecutively to the hospital of the University of Regensburg with
the clinically suspected diagnosis ‘‘SSc’’. The diagnosis of SSc
was confirmed by histological examination and according to the
criteria of the American College of Rheumatology for SSc (Sub-
committee for scleroderma criteria of the American Rheumatism
Association diagnostic and therapeutic criteria committee, 1980).
Routine skin biopsies of affected areas were obtained in all SSc
patients. Parts of the biopsies were fixed in formalin, paraffin em-
bedded and subsequently histological sections were stained with
hematoxylin and eosin. Furthermore, parts of the biopsies were
used for DNA isolation and isolation of skin fibroblasts, respec-
tively.
Histological examination of the samples showed fibrosis of the
dermis with hyalinization and homogenization of the collagen bun-
dles, as confirmed also by a collagen-specific stain (Masson–
Goldner stain). Two of the patients presented an inflammatory
stage with marked, mostly perivascular inflammatory cell infiltrates
(lymphocytes, plasma cells, and macrophages) in the dermis. The
other 16 patients presented a sclerotic stage with no or only sparse
inflammatory infiltrates.
In addition, skin biopsies of four healthy individuals and five
patients with inflammatory skin disorders (contact dermatitis,
vasculitis, urticaria, eczema) were obtained and served as con-
trols for immunohistochemical examinations.
Informed consent was obtained from all patients and the study
was approved by the local ethics committee. The study was con-
ducted according to the Declaration of Helsinki Guidelines.
Frequency of MCP-1 genotypes was compared to 139 healthy
controls from the same geographic region (Muhlbauer et al, 2003).
Patients and controls were of Caucasian origin.
DNA isolation and MCP-1 genotyping Genomic DNA from SSc
patients was extracted from skin tissue using a commercially
available DNA isolation kit following the manufacturer’s instructions
(Qiagen, Hilden, Germany). The G to A polymorphisms at position
2518 of the MCP-1 gene was analyzed by performing PCR and
subsequent restriction fragment length polymorphism (RFLP) anal-
ysis. PCR was performed under standard conditions (35 cycles,
annealing temperature: 551C) in a total reaction volume of 50 mL
containing 2 mL of diluted genomic DNA, using the following pair of
primers: forw: 50-CCG AGA TGT TCC CAG CAC AG-30 and rev: 50-
CTG CTT TGC TTG TGC CTC TT-30. PCR products were digested
by PvuII, and the resulting fragments were separated by elect-
rophoresis in a 2% agarose gel and visualized by ethidium bromide
staining. With the 2518 A polymorphic base, the recognition se-
quence 50-CAG/CTG-30 is modified to 50-CAG/CTA-30, which is not
cut by PvuII.
Controls consisted of healthy individuals that had already been
genotyped for a recent study of our group (Muhlbauer et al, 2003).
MCP-1 immunohistochemical studies Immunohistochemistry
for MCP-1 was performed on formalin-fixed and paraffin-embed-
ded 2-mm-thick sections obtained from all 18 patients with SSc,
from four healthy controls and from five patients with inflammatory
skin disorders different from SSc (urticaria, contact dermatitis,
vasculitis, eczema). The slides were deparaffinized by xylol and
decreasing concentrations of ethanol. The sections were then
treated with citric acid (2.1 g per liter, pH 6.0) and steamed for
30 min followed by cooling for further 30 min. Serial sections were
immunostained for MCP-1 (anti-MCP-1 human monoclonal anti-
body, 1:100 dilution, 5D3-F7, Alexis Biochemicals, Gru¨nberg, Ger-
many) according to the manufacturer’s recommendations and
counterstained with hemalaun. Negative controls were performed
by omitting the primary antibody.
MCP-1 expression was evaluated semiquantitatively using a
score (þ þ , strong; þ , moderate;  , weak; , negative) repre-
senting the product of the intensity of immunosignals and the number
of positive cells as previously described (Yamamoto et al, 2001a).
All diagnoses were confirmed by a second dermatopathologist
blind of clinical information and without knowledge of the patients’
genotypes.
Isolation and culture of human dermal ﬁbroblasts Primary hu-
man dermal fibroblast strains were established by outgrowth from
biopsies of involved skin from patients with SSc. Fibroblasts were
maintained in Dulbecco’s modified Eagle’s Medium (DMEM) sup-
plemented with 10% fetal calf serum (FCS), 2 mM glutamine, 50 mg
per mL sodium ascorbate, 100 U per mL penicillin, and 100 mg per
mL streptomycin and grown as monolayers on plastic Petri dishes
in a humidified atmosphere of a CO2 incubator at 371C. Fibroblast
cultures were subcultured by trypsinisation and used between the
third and the tenth passages.
MCP-1 genotyping of the fibroblast strains was performed ac-
cording to the methods described above. Three SSc fibroblast cell
lines with different genotypes were chosen for further experiments
(one cell line: A/A, one cell line: A/G, and one cell line: G/G,
respectively.)
MCP-1 expression of dermal ﬁbroblasts Fibroblasts were stim-
ulated with recombinant human TNF (10 ng per mL; R&D Systems,
Wiesbaden-Nordenstadt, Germany) for 6 and 16 h, respectively.
After 6 h of stimulation, RNA was isolated using the RNeasy Mini
Kit including a RNase-free DNase step following the instructor’s man-
ual (Qiagen). RNA amounts were analyzed by using a fluorescence
microplate reader and following the instructor’s manual of the Ribo-
Green RNA Quantitation Reagent and Kit (MoBiTec, Go¨ttingen,
Germany). Integrity of the RNA was verified by agarose gel elect-
rophoresis and by visualization of ribosomal bands with ethidium bro-
mide staining. First strand cDNA was synthesized using 1 mg of total
RNA and the AMV-reverse transcription reaction (Promega, Madison,
Wisconsin). MCP-1 mRNA expression was quantified using real-time
PCR technology (Lightcycler, Roche Diagnostics, Mannheim, Ger-
many) with specific sets of primers for human MCP-1 and b-actin
based on published sequences: b-actin forward 50-CTA CGT CGC
CCT GGA CTT CGA GC-30 and b-actin reverse 50-GAT GGA GCC
GCC GAT CCA CAC G-30; MCP-1 forward 50-GCG GAG CTA TAG
AAG AAT CAC-30 and MCP-1 reverse 50-TTG GGT TGT GGA GTG
AGT GT-30.
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Furthermore, after 16 h stimulation with TNF supernatants were
collected, centrifuged to remove cellular debris and MCP-1 protein
concentrations were analyzed by a sandwich ELISA following the
instructor’s manuals (Biosource, Camarillo, California).
Unstimulated SSc fibroblasts were analyzed to determine basal
MCP-1 mRNA expression and MCP-1 secretion, respectively.
Statistical analysis Results are expressed as mean  SD. Gen-
otype frequencies are reported with their group percentages, a
two-sided Fisher’s Exact Test was used for comparison between
these groups. Independent in vitro experiments were performed in
triplicate. Statistical significance was evaluated in paired analyses
using the Student’s paired t test or the U-test (non-parametric),
depending on the data distribution. A p value o0.05 was con-
sidered statistically significant.
Statistical evaluations were performed with the SPSS-10 for
Windows statistical computer package (SSPS, Chicago, Illinois).
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